R&D channel feed

Mer­ck to move glob­al head­quar­ters, re­turn­ing to an old home

6 years ago

'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

6 years ago

Small biotech Oys­ter Point sets up pitch to dis­rupt dry eye mar­ket with nasal spray

6 years ago

De­railed by the pan­dem­ic, FDA of­fers CRISPR, Ver­tex drug pro­gram VIP sta­tus for its come­back play

6 years ago
FDA+

Top Genen­tech re­searcher steps away and Roche turns to the Broad for a star re­place­ment play­er

6 years ago
People

A ground­break­ing can­cer drug nabs fast OK, giv­ing Eli Lil­ly boast­ing rights as a ri­val speeds close be­hind

6 years ago
FDA+

Ovid's lead drug shows promis­ing ef­fi­ca­cy sig­nal in Frag­ile X syn­drome study, but op­ti­mal dos­ing reg­i­men is un­clear for path for­ward

6 years ago

Amid lab space scarci­ty, a life sci­ences com­plex to rise in South San Fran­cis­co hub

6 years ago
Deals

More than 1,000 clin­i­cal tri­als were stopped by the pan­dem­ic — in­clud­ing dozens in PhI­II

6 years ago
Bioregnum
Coronavirus

Covid-19 roundup: Can­cer drug re­search takes a big hit, sur­vey finds; Chaot­ic remde­sivir dis­tri­b­u­tion con­tin­ues to anger doc­tors

6 years ago
Coronavirus

Or­chard Ther­a­peu­tics prunes jobs to re­fo­cus pri­or­i­ties on big­ger fruit

6 years ago

Two years af­ter a wrench­ing set­back, Pro­tag­o­nist touts a slice of da­ta and sets sights on piv­otal tri­al in a sur­pris­ing place: the blood

6 years ago

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots of ques­tions for lat­er

6 years ago
Bioregnum
Opinion

Flag­ship-backed Evelo Bio­sciences joins Covid-19 hunt with pro­pos­al for bac­te­ria tri­al

6 years ago
Coronavirus

As­traZeneca's block­buster Farx­i­ga se­cures land­mark ap­proval in heart fail­ure pa­tients, re­gard­less of whether they have di­a­betes

6 years ago
FDA+

J&J R&D ex­ec Na­jat Khan — and da­ta sci­ence — are get­ting an el­e­vat­ed role at the phar­ma gi­ant

6 years ago
People
AI

A risky bet on a long-de­layed CAR-T drug now faces a do-or-die dead­line — where any slip can kill a $9 CVR

6 years ago
FDA+

Roche flash­es new 16-week bis­pe­cif­ic AMD da­ta, set­ting eyes on pair of PhI­II tri­als

6 years ago

Af­ter big 2016 set­back, field of mi­cro­bio­me-based drugs gets in­jec­tion of promise with pos­i­tive sig­nal from Re­bi­otix piv­otal study

6 years ago

Oust­ed BAR­DA chief Rick Bright blasts HHS of­fi­cial for a long record of im­prop­er in­ter­fer­ence that pre­ced­ed the pan­dem­ic

6 years ago
People

Ake­bia touts da­ta for two PhI­II stud­ies, set­ting up show­down with As­traZeneca, Fi­bro­Gen

6 years ago

Two years af­ter U2 dis­ap­point­ment, TG Ther­a­peu­tics wins back in­vestors with PFS win — set­ting the stage for NDA

6 years ago

A UCSD cen­ter that's been fa­cil­i­tat­ing Covid-19 clin­i­cal re­search gets $55M from NIH to boost trans­la­tion­al work

6 years ago
Discovery

Prax­is Pre­ci­sion Med­i­cines launch­es with $100M and bold sights on long-eva­sive neu­ro­log­i­cal dis­or­ders

6 years ago
Financing
Startups
First page Previous page 202203204205206207208 Next page Last page
A service from the Financial Times